India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, according to market estimates.
US pharma giant Eli Lilly's Mounjaro can prove crucial in treatment of obesity & type 2 diabetes. Launched in the US in 2022, it has since become a global blockbuster.
While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its effectiveness in obesity management come out in 3 months.
Tirzepatide is a type 2 diabetes and obesity drug sold by US firm Eli Lilly under the brand names Mounjaro and Zepbound. It may take around 6 months for it to be launched in India.
Pharma giants were responding to petition in Kerala HC seeking compulsory licences for their HER2-negative breast cancer drugs, which would allow cheaper, generic versions to be made.
Patients who got a weekly injection of the experimental anti-obesity drug retatrutide lost up to 24 per cent of their body weight in 48 weeks, show phase-2 trials published this week.
BHL says it can produce Baricitinib for as cheap as Rs 14 (for 1mg). US pharma giant Eli Lilly, which holds exclusive licence for the drug, manufactures it at an average cost of Rs 3,230.
If extremely heavy rainfall can cause such damage without a rare event like a cloudburst, it should leave the system working toward India’s disaster preparedness thinking.
One such website has drawn particular scrutiny for spreading fake stories that have upset not only the Indian but also foreign defence firms by falsely attributing misinformation.
Standing up to America is usually not a personal risk for a leader in India. Any suggestions of foreign pressure unites India behind who they see as leading them in that fight.
COMMENTS